Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 12/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848278 | 1.00 | CA12 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848221 | 0.94 | CA12 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848264 | 0.94 | CA12 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848206 | 0.93 | CA12 (0.54) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848266 | 0.93 | CA12 (0.54) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848282 | 0.91 | CA12 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848283 | 0.91 | CA12 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17821315 | 0.91 | PPARG (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17821316 | 0.91 | PPARG (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17848323 | 0.90 | PPARG (0.57) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | claimed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | KRAS, NRAS, HRAS | CA12 3756/4885CA1 2386/4885CA2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.